Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Agalsidase beta - Sanofi Genzyme

Drug Profile

Agalsidase beta - Sanofi Genzyme

Alternative Names: Fabrazyme; Recombinant human α-galactosidase A - Sanofi Genzyme

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Canada; Genzyme Corporation
  • Developer Genzyme Canada; Icahn School of Medicine at Mount Sinai; Sanofi Genzyme
  • Class Galactosidases; Glycoproteins; Isoenzymes
  • Mechanism of Action Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fabry's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fabry's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Aug 2017 Discontinued - Phase-III for Fabry's disease (Early-stage disease, In adolescents, In children, Treatment-naive) in Norway, Netherlands, Canada, Brazil, Argentina, Poland, United Kingdom, Czech Republic, France and USA (IV), because not listed on Sanofi Genzyme pipeline, August 2017
  • 03 Mar 2015 Launched for Fabry's disease in Brazil, Chile, Argentina, Mexico, Malaysia, Turkey, Russia, Switzerland, Hong Kong and India (IV) prior to March 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top